Renal Sympathetic Denervation for the Management of Chronic Hypertension (RELIEF)
Primary Purpose
Uncontrolled Hypertension
Status
Completed
Phase
Not Applicable
Locations
Czech Republic
Study Type
Interventional
Intervention
Biosense Webster Celcius Thermacool catheter
Sponsored by

About this trial
This is an interventional treatment trial for Uncontrolled Hypertension focused on measuring renal sympathetic denervation, renal catheter ablation, hypertension
Eligibility Criteria
Inclusion Criteria:
- ≥ 18 and ≤ 85 years of age
- Uncontrolled hypertension (defined as SBP ≥ 140 mmHg during 24Hr Ambulatory BP monitoring)
- Current treatment with ≥ 3 anti-hypertensive drugs (including at least one diuretic)
- Accessibility of renal vasculature
- Ability to understand the requirements of the study
- Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements
Exclusion Criteria:
- Secondary cause of hypertension
- White coat hypertension
- Estimated GFR < 45
- Type 1 Diabetes
- Known renovascular abnormalities (eg, renal artery stenosis, previous renal artery stenting or angioplasty)
- Life expectancy <1 year for any medical condition
Sites / Locations
- Fakultní nemocnice u sv. Anny v Brně
- Na Homolce Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Biosense Webster Celcius Thermacool catheter
renal angiogram only
Arm Description
These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
Control Group: Control arm will not receive intervention but will be followed for 1 year.
Outcomes
Primary Outcome Measures
Change in 24-hour ambulatory BP
Differences in 24-hour ambulatory blood pressure measurements recorded at baseline and at 6 months for each patient.
Secondary Outcome Measures
change in office BP
Difference in office blood pressure measurements at 6 months and at 12 months as compared to baseline.
change in ambulatory BP
Difference in 24 hour ambulatory blood pressure measurements at 12 months compared to baseline
Renal artery dimensions
Change in renal artery dimensions at 6 months.
Creatinine
Differences in creatinine measurements recorded at baseline and at 6 months for each patient.
Full Information
NCT ID
NCT01628172
First Posted
June 12, 2012
Last Updated
June 28, 2016
Sponsor
Vivek Reddy
Collaborators
Biosense Webster, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01628172
Brief Title
Renal Sympathetic Denervation for the Management of Chronic Hypertension
Acronym
RELIEF
Official Title
Renal Sympathetic Denervation for the Management of Chronic Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
March 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Vivek Reddy
Collaborators
Biosense Webster, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Despite the development of numerous drug therapies designed to treat hypertension, it remains a considerable and poorly managed health, social and economic burden. For various reasons, including the significant health care costs of treatment, there are estimates that up to 65% of hypertensive patients have untreated and/or uncontrolled blood pressure (BP).
Aside from its impact on renal function, chronic hypertension significantly increases the risk for stroke, coronary artery disease, heart failure, and vascular disease. It is believed to be involved in the progression of cardiac arrhythmias. This link between hypertension and cardiovascular health has been well described; as has their combined effect on the aging and obesity-battling Western world.
The recently published results of the Symplicity HTN-2 trial (Renal sympathetic denervation in patients with treatment resistant hypertension) establishing the therapeutic benefit of catheter-based renal sympathetic denervation for hypertension, have enormous potential for the management of a large and challenging patient population. The proposed, multicenter trial will attempt to confirm and expand on this promising data by conducting a double-blinded, placebo-controlled trial.
Patients may qualify to participate in this research study if their doctor has determined that they have drug-resistant, chronic hypertension.
Overall participation in this research study should be about 13 months which includes about 1 month to start the study procedure and 12 months of follow-up after the study procedure.
Detailed Description
Patients who qualify for the study and provide consent will undergo a renal angiogram in order to assess suitability for catheter-based renal sympathetic denervation. A renal angiogram is an x-ray study of the blood vessels in the kidney to evaluate for blockage, and abnormalities that could be affecting the blood supply to the kidney. It is performed by injecting contrast dye through a catheter (a tiny tube) into the blood vessels of the kidney. The study doctor will assess whether the renal arteries are suitable to receive catheter-based renal denervation.
Both groups will receive sedation or anesthesia prior to the beginning of the procedure.
The first group will undergo catheter-based sympathetic renal denervation. Renal Sympathetic Denervation is a procedure that uses a catheter probe inserted into the renal (kidney) artery that deactivates the nerves that are linked to high blood pressure.
The second group will only receive renal angiography without the delivery of ablative energy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uncontrolled Hypertension
Keywords
renal sympathetic denervation, renal catheter ablation, hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
96 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Biosense Webster Celcius Thermacool catheter
Arm Type
Experimental
Arm Description
These subjects will undergo catheter-based sympathetic renal denervation. Ablation arm
Arm Title
renal angiogram only
Arm Type
No Intervention
Arm Description
Control Group: Control arm will not receive intervention but will be followed for 1 year.
Intervention Type
Device
Intervention Name(s)
Biosense Webster Celcius Thermacool catheter
Other Intervention Name(s)
sympathetic renal denervation, Ablation arm
Intervention Description
catheter-based sympathetic renal denervation
Primary Outcome Measure Information:
Title
Change in 24-hour ambulatory BP
Description
Differences in 24-hour ambulatory blood pressure measurements recorded at baseline and at 6 months for each patient.
Time Frame
baseline and at 6 months
Secondary Outcome Measure Information:
Title
change in office BP
Description
Difference in office blood pressure measurements at 6 months and at 12 months as compared to baseline.
Time Frame
baseline, 6 months, and 12 months
Title
change in ambulatory BP
Description
Difference in 24 hour ambulatory blood pressure measurements at 12 months compared to baseline
Time Frame
baseline and at 12 months
Title
Renal artery dimensions
Description
Change in renal artery dimensions at 6 months.
Time Frame
baseline and at 6 months
Title
Creatinine
Description
Differences in creatinine measurements recorded at baseline and at 6 months for each patient.
Time Frame
baseline and at 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
≥ 18 and ≤ 85 years of age
Uncontrolled hypertension (defined as SBP ≥ 140 mmHg during 24Hr Ambulatory BP monitoring)
Current treatment with ≥ 3 anti-hypertensive drugs (including at least one diuretic)
Accessibility of renal vasculature
Ability to understand the requirements of the study
Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements
Exclusion Criteria:
Secondary cause of hypertension
White coat hypertension
Estimated GFR < 45
Type 1 Diabetes
Known renovascular abnormalities (eg, renal artery stenosis, previous renal artery stenting or angioplasty)
Life expectancy <1 year for any medical condition
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vivek Reddy, MD
Organizational Affiliation
Icahn School of Medicine at Mount Sinai
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fakultní nemocnice u sv. Anny v Brně
City
Brno
ZIP/Postal Code
53, 656 91
Country
Czech Republic
Facility Name
Na Homolce Hospital
City
Prague
ZIP/Postal Code
15030
Country
Czech Republic
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
19332353
Citation
Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009 Apr 11;373(9671):1275-81. doi: 10.1016/S0140-6736(09)60566-3. Epub 2009 Mar 28.
Results Reference
background
PubMed Identifier
19075105
Citation
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009 Jan 27;119(3):e21-181. doi: 10.1161/CIRCULATIONAHA.108.191261. Epub 2008 Dec 15. No abstract available. Erratum In: Circulation. 2009 Jan 27;119(3):e182. Circulation. 2010 Jul 6;122(1):e11. Circulation. 2011 Oct 18;124(16):e424.
Results Reference
background
PubMed Identifier
15652604
Citation
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005 Jan 15-21;365(9455):217-23. doi: 10.1016/S0140-6736(05)17741-1.
Results Reference
background
PubMed Identifier
19022154
Citation
Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol. 2008 Nov 25;52(22):1749-57. doi: 10.1016/j.jacc.2008.08.036.
Results Reference
background
PubMed Identifier
18852389
Citation
Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008 Nov;52(5):818-27. doi: 10.1161/HYPERTENSIONAHA.108.113357. Epub 2008 Oct 13.
Results Reference
background
PubMed Identifier
18574054
Citation
Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24;117(25):e510-26. doi: 10.1161/CIRCULATIONAHA.108.189141.
Results Reference
background
PubMed Identifier
11856913
Citation
DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens. 2002 Mar;11(2):197-200. doi: 10.1097/00041552-200203000-00011.
Results Reference
background
PubMed Identifier
9016301
Citation
DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997 Jan;77(1):75-197. doi: 10.1152/physrev.1997.77.1.75.
Results Reference
background
PubMed Identifier
2828236
Citation
Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension. 1988 Jan;11(1):3-20. doi: 10.1161/01.hyp.11.1.3. No abstract available.
Results Reference
background
PubMed Identifier
14610101
Citation
Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, Hastings J, Aggarwal A, Esler MD. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension. 2004 Feb;43(2):169-75. doi: 10.1161/01.HYP.0000103160.35395.9E. Epub 2003 Nov 10.
Results Reference
background
PubMed Identifier
13024041
Citation
MORRISSEY DM, BROOKES VS, COOKE WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet. 1953 Feb 28;1(6757):403-8. doi: 10.1016/s0140-6736(53)91589-x. No abstract available.
Results Reference
background
PubMed Identifier
13061307
Citation
SMITHWICK RH, THOMPSON JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953 Aug 15;152(16):1501-4. doi: 10.1001/jama.1953.03690160001001. No abstract available.
Results Reference
background
PubMed Identifier
13821037
Citation
EVELYN KA, SINGH MM, CHAPMAN WP, PERERA GA, THALER H. Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects. Am J Med. 1960 Feb;28:188-221. doi: 10.1016/0002-9343(60)90184-4. No abstract available.
Results Reference
background
PubMed Identifier
10075613
Citation
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999 Mar 16;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002.
Results Reference
background
PubMed Identifier
14656957
Citation
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2. Epub 2003 Dec 1.
Results Reference
background
PubMed Identifier
18779438
Citation
Grassi G, Seravalle G, Quarti-Trevano F, Dell'Oro R, Bombelli M, Cuspidi C, Facchetti R, Bolla G, Mancia G. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension. 2008 Nov;52(5):925-31. doi: 10.1161/HYPERTENSIONAHA.108.116368. Epub 2008 Sep 8.
Results Reference
background
PubMed Identifier
3326559
Citation
DiBona GF. Renal innervation and denervation: lessons from renal transplantation reconsidered. Artif Organs. 1987 Dec;11(6):457-62. doi: 10.1111/j.1525-1594.1987.tb02710.x.
Results Reference
background
PubMed Identifier
2899801
Citation
O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet. 1988 Aug 13;2(8607):397. doi: 10.1016/s0140-6736(88)92867-x. No abstract available.
Results Reference
background
PubMed Identifier
12370222
Citation
Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002 Oct 8;106(15):1974-9. doi: 10.1161/01.cir.0000034043.16664.96.
Results Reference
background
PubMed Identifier
18799718
Citation
Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009 May;20(5):933-9. doi: 10.1681/ASN.2008040402. Epub 2008 Sep 17.
Results Reference
background
PubMed Identifier
12623969
Citation
DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003 Mar;41(3 Pt 2):621-4. doi: 10.1161/01.HYP.0000047205.52509.8A. Epub 2002 Dec 16.
Results Reference
background
PubMed Identifier
12609004
Citation
Fagius J. Sympathetic nerve activity in metabolic control--some basic concepts. Acta Physiol Scand. 2003 Mar;177(3):337-43. doi: 10.1046/j.1365-201X.2003.01086.x.
Results Reference
background
PubMed Identifier
14981063
Citation
Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004 Apr;43(4):699-706. doi: 10.1161/01.HYP.0000121881.77212.b1. Epub 2004 Feb 23.
Results Reference
background
PubMed Identifier
14736957
Citation
Luippold G, Beilharz M, Muhlbauer B. Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats. Nephrol Dial Transplant. 2004 Feb;19(2):342-7. doi: 10.1093/ndt/gfg584.
Results Reference
background
PubMed Identifier
12160195
Citation
Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002 Aug;15(8):717-24. doi: 10.1016/s0895-7061(02)02959-x.
Results Reference
background
PubMed Identifier
7485145
Citation
Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995 Nov;26(5):861-5. doi: 10.1016/0272-6386(95)90456-5.
Results Reference
background
Learn more about this trial
Renal Sympathetic Denervation for the Management of Chronic Hypertension
We'll reach out to this number within 24 hrs